Lunai Bioworks Inc. develops AI-enabled life sciences platforms for drug discovery, precision therapeutics and chemical defense applications. Company news centers on the Augusta platform, BioSymetrics' phenotypic screening and machine-learning capabilities, and programs tied to central nervous system diseases, oncology and biodefense.
Recurring updates include intellectual property additions, patent issuances, commercial collaborations, defense-focused chemical threat assessment work, and capital transactions used to support platform expansion. Recent company developments also cover CNS delivery technologies, neurotherapeutic patent assets, patient-stratification methods, and the integration of clinical, genomic and phenotypic data into drug discovery workflows.
Lunai Bioworks (NASDAQ: LNAI) completed an NIH STTR commercial milestone creating high-resolution, multidimensional behavioral signatures of ethanol exposure and withdrawal and has launched a commercial Alcohol Use Disorder (AUD) drug-discovery program.
The program uses scalable high-throughput vertebrate screening, targets underexplored mechanisms, is supported by NIH funding, and is run in collaboration with Dr. Calum MacRae at Brigham and Women's Hospital/Harvard Medical School.
Company cites a large unmet need: ~30 million U.S. individuals affected, ~95% receiving no effective pharmacologic treatment, and a ~$250 billion annual economic cost.
Lunai Bioworks (NASDAQ: LNAI) was featured in International Business Times on Dec 17–18, 2025 for advancing AI-enabled drug discovery and active partnership discussions around multiple CNS programs, including Parkinson's, Alzheimer's and epilepsy.
The piece highlights Lunai's Augusta platform integrating longitudinal clinical data, large-scale proteomics and phenotypic analysis, use of PPMI Parkinson's data to identify patient subtypes and targets, and the company's focus on non-dilutive partnerships to extend runway and validate the platform.
Market context cited includes recent landmark AI-drug deals, an estimated $240 billion revenue-at-risk tailwind, ~$1.3 trillion capital for external innovation, ~11 million shares sold short vs a post-split float of ~23 million, and a 2025 market-cap reset from >$350M to $30M.
Lunai Bioworks (NASDAQ: LNAI) announced identification of three clinically relevant Parkinson's disease subtypes and prioritized drug targets intended to accelerate proof-of-concept programs and strategic partnerships.
Analysis integrated longitudinal clinical and proteomic data from >650 participants and ~4,500 proteomic probes (median follow-up ≥2.5 years), linking subtypes to rapid progression, cognitive decline, and functional impairment. Lunai is initiating experimental validation, preclinical model development, and biomarker qualification while evaluating co-development opportunities in a market projected to exceed $13 billion by the 2030s.
Lunai Bioworks (NASDAQ: LNAI) announced it has secured a first letter of intent (LOI) to license its next‑generation dendritic cell combination therapy (DCCT) after peer‑reviewed publication and independent expert review. In humanized mouse models of pancreatic cancer, the DCCT produced complete regression of primary and metastatic tumors with no recurrence and 80–90% tumor size reduction across two studies. Lunai also reported a successful pre‑IND meeting with the FDA and plans for formal licensing negotiations and pre‑IND activities in early 2026 toward a proposed Phase I trial for high‑need solid tumors.
Lunai Bioworks (NASDAQ: LNAI) announced that a second‑generation, clinical‑grade dendritic cell (DC) therapy produced complete regression of primary and metastatic pancreatic tumors in preclinical humanized mouse models.
The Brief Report was published in Vaccines on Nov 2, 2025 and describes an optimized, clinically compliant construct that preserves the original product's efficacy while improving promoter and manufacturing elements to support IND‑enabling studies.
The therapy triggered robust activation of cytotoxic T cells and NK cells, and the company says the data advance partnering conversations and the platform's translation toward clinical development.
Lunai Bioworks (NASDAQ:LNAI) announced early results from an AI-driven platform that identifies compounds interacting with acetylcholinesterase (AChE), the molecular target of nerve agents. The company reported its predictive model achieved 0.94 AUROC for distinguishing active AChE inhibitors from inactive compounds and flagged previously unidentified candidate neurotoxic compounds for follow-up. Lunai plans to combine the AI predictions with behavioral zebrafish profiling to observe real-time physiological effects and prioritize countermeasures. The company also embedded the model in a partner dashboard to enable collaborative chemical-structure screening for potential neurotoxicity.
Lunai Bioworks (NASDAQ:LNAI) subsidiary BioSymetrics and academic partners published a Nature Communications study (Oct 16, 2025) reporting prognostic serum protein biomarkers for Duchenne muscular dystrophy (DMD).
The multi‑institutional analysis used the SomaScan proteomics platform on >700 longitudinal serum samples from European and U.S. cohorts and identified proteins including RGMA, ART3, and ANTXR2 that associate with motor performance and predict outcomes such as loss of ambulation and upper‑limb decline.
Authors say these minimally invasive biomarkers could refine clinical trial enrollment, improve stratification, and support more personalized patient management, while results were cross‑cohort validated and controlled for age and corticosteroid use.
Lunai Bioworks (Nasdaq:LNAI) announced it has regained compliance with Nasdaq's minimum bid price requirement under Listing Rule 5550(a)(2). Nasdaq staff had notified the company on April 14, 2025 that LNAI's common stock failed to maintain a $1.00 minimum bid over the prior 30 business days. Staff determined the closing bid price was at or above $1.00 for 11 consecutive business days from September 30, 2025 through October 14, 2025, restoring compliance and leaving the company eligible to remain listed on The Nasdaq Capital Market. Management said the milestone supports its focus on advancing an AI-powered platform for drug discovery and biodefense.
Lunai Bioworks (Nasdaq:LNAI) launched a preclinical Alzheimer's program using its AI platform Augusta, reporting up to a 35% improvement in diagnostic accuracy by combining MRI, genomics, and metabolomics versus MRI alone. BioSymetrics, a wholly owned subsidiary, signed its first commercial contract last week to identify early Alzheimer's markers. Results were benchmarked on the ADNI dataset and used automated optimization across 22,000 MRI processing runs. The platform supports real-time distributed analysis via cloud architecture and is positioned to extend prior Parkinson's findings into broader neurodegenerative diagnostics.
Lunai Bioworks (NASDAQ:LNAI), formerly known as Renovaro Inc., has unveiled its new corporate identity alongside a 10:1 reverse stock split that reduces outstanding shares from 231.8 million to 23.2 million. The company's rebranding reflects its strategic focus on AI-powered drug discovery and biodefense.
Key developments include the launch of a proprietary transformer-based platform for neurotoxicity intelligence, advancement of a preclinical Parkinson's Disease biomarker program through subsidiary BioSymetrics, and securing a multi-year NIH STTR grant. The company's Augusta platform aims to advance precision neurology through AI-integrated therapeutics and biomarker intelligence.